International Journal of STD & AIDS > Volume 19, Number 6 > Pp. 416-417

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Street, E J Articles by Hale, A D PubMed PubMed Citation Social Bookmarking                      What's this?

Audit reports

An audit of baseline HIV-1 genotypic resistance testing in a UK provincial city

E J Street MRCP DipGUM ^* , N R Armstrong MRCP DipGUM ^*, E F Monteiro FRCP ^* and A D Hale MA FRCPath 

^* Centre for Sexual Health; Department of Virology, Leeds General Infirmary, Leeds, UK

Correspondence to: Dr Emma J Street, Centre for Sexual Health, Leeds General Infirmary, Leeds LS1 3EX, UK Email: Emma.Street{at}leedsth.nhs.uk

Baseline HIV-1 resistance testing is recommended in the 2005 BHIVA treatment guidelines. We compared the practice in our clinic with these guidelines. The aim of this study was to assess the prevalence of transmitted resistance in all antiretroviral therapy-naïve patients identified from our virology resistance test database. In 2006, 93% of all newly diagnosed patients had a baseline HIV-1 genotypic resistance test performed. The estimated prevalence of transmitted resistance was 8% in newly diagnosed patients and 7% overall with the majority in subtype B. These findings are in keeping with nationally reported data. It was of concern that we also identified a number of patients who had tested negative in the previous year.

Key Words: audit • HIV • genotypic resistance testing

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?